Sign In
Buy IMCR
$29.20
-0.150 (-0.511%)
At Close: Jun 23, 2026
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why
01:01pm, Tuesday, 17'th Feb 2026
Immunocore (IMCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of “Moderate Buy” from Brokerages
04:44am, Monday, 09'th Feb 2026
Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ: IMCR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen analysts that are currently covering t
Immunocore announces R&D leadership evolution
07:00am, Friday, 30'th Jan 2026
Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice
Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock?
08:13am, Thursday, 22'nd Jan 2026
Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in
Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:26pm, Wednesday, 14'th Jan 2026
Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
07:00am, Friday, 09'th Jan 2026
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US communit
Immunocore (IMCR) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Thursday, 08'th Jan 2026
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Moderate Buy” by Brokerages
03:24am, Sunday, 21'st Dec 2025
Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ: IMCR - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve brokerages that are currently covering the stock, Mar
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of “Moderate Buy” by Brokerages
04:08am, Wednesday, 26'th Nov 2025
Immunocore Holdings PLC Sponsored ADR (NASDAQ: IMCR - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve research firms that are currently covering the company,
Immunocore to present at upcoming investor conferences
07:00am, Monday, 10'th Nov 2025
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst
11:28pm, Friday, 07'th Nov 2025
Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentime
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting
08:00am, Friday, 07'th Nov 2025
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA
Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say
11:00am, Thursday, 06'th Nov 2025
Although the revenue and EPS for Immunocore (IMCR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall
Immunocore reports third quarter financial results and provides a business update
07:00am, Thursday, 06'th Nov 2025
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-A
Growth Picks: 3 Low-Cost Stocks That Could Double in Value
06:42pm, Monday, 27'th Oct 2025
Many stocks are objectively overvalued. That can make it difficult for investors to find opportunities for stocks with the potential to double.
